Please login to the form below

Not currently logged in
Email:
Password:

immuno-oncology

This page shows the latest immuno-oncology news and features for those working in and with pharma, biotech and healthcare.

FDA green lights BMS’ multiple myeloma combo

FDA green lights BMS’ multiple myeloma combo

The] approval reinforces the importance of Immuno-Oncology in blood cancers and expands the role of Empliciti to address the needs of relapsed or refractory multiple myeloma patients.”.

Latest news

  • AZ says target of $45bn sales by 2023 still achievable AZ says target of $45bn sales by 2023 still achievable

    Lynparza (olaparib) for ovarian and breast cancer more than doubled to $438m, while a new lung cancer indication transformed immuno-oncology drug Imfinzi (durvalumab) pushing sales to $371m.

  • The Midas Touch The Midas Touch

    For example, Boehringer Ingelheim is making choices like this as the company continues its shopping spree in immuno-oncology with the takeover of Vira Therapeutics, a smallish bet with potentially high

  • Is GSK planning to exit the respiratory business? Is GSK planning to exit the respiratory business?

    Barron made much of GSK’s immunology and immuno-oncology portfolio on the company’s interim results call, saying it has 27 new molecular entities (NMEs) in these areas which account ... to an explosion of new studies and product launches in

  • BMS CEO tackles investor ‘frustrations’ on immuno-oncology BMS CEO tackles investor ‘frustrations’ on immuno-oncology

    BMS CEO tackles investor ‘ frustrations’ on immuno-oncology. Company faces pressure from competitors in renal cell carcinoma. ... Bristol-Myers Squibb chief executive Giovani Caforio barely mentioned the company’s finances on its third-quarter

  • AZ swells immuno-oncology pipeline with Innate deal AZ swells immuno-oncology pipeline with Innate deal

    AZ swells immuno-oncology pipeline with Innate deal. Deal gives access to natural killer cell immunotherapy. ... For another $20m, AZ also gets an option on four other immuno-oncology molecules from Innate’s pipeline that have yet to be agreed.

More from news
Approximately 62 fully matching, plus 252 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 3 fully matching, plus 46 partially matching documents found.

Latest appointments

  • BMS appoints CCO, Stephen Davies joins Eisai and more BMS appoints CCO, Stephen Davies joins Eisai and more

    There, he led the discovery of novel immuno-oncology and autoimmune therapeutic programmes. ... class new treatments for cancer patients and to help transform the company into a world-class immuno-oncology leader.".

  • Redx Pharma appoints new chief medical officer Redx Pharma appoints new chief medical officer

    Dr Saunders has worked in the oncology field for over 25 years and has experience in all aspects of the clinical development of oncology drugs. ... He joins the UK biotech from Lytix Biopharma, a Norweigan immuno-oncology biotech, where he also served as

  • Targovax appoints Michael Bogenstaetter as chief business officer Targovax appoints Michael Bogenstaetter as chief business officer

    Targovax appoints Michael Bogenstaetter as chief business officer. He joins the immuno-oncology biotech from Interim Assignments.

  • Lilly bolsters its oncology team Lilly bolsters its oncology team

    Lilly bolsters its oncology team. Kimberly Blackwell is appointed VP early phase development, immuno-oncology. ... Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique

  • BMS’ Dr Mike Burgees joins Turnstone Biologics BMS’ Dr Mike Burgees joins Turnstone Biologics

    BMS’ Dr Mike Burgees joins Turnstone Biologics. He joins the immuno-oncology group as its president of R&D. ... Mike’s oncology expertise will be instrumental in advancing the development of our next-generation viral immunotherapies and powerful

More from appointments
Approximately 0 fully matching, plus 31 partially matching documents found.

Latest from PMHub

  • SWITCHED ONcology

    We are stronger together. We are Switched ON. Switched ONcology is the latest thought leadership campaign from the award-winning Havas lynx portfolio. ... The campaign provides our partners with deeper insight, smarter ideas and more meaningful

  • The Big Communication - matching unprecedented clinical advances in immunotherapy with transformative communication

    In this white paper, we explore the exciting new frontier of cancer treatment - immuno-oncology (IO) - and what it means for how we communicate with healthcare professionals, patients and carers.

  • Medical information in precision medicine

    We are not treating the partnership as just another oncology medicine – it’ s a molecular information service, and that requires a great level of scientific understanding.

  • Video: Immuno-oncology therapies

    Video: Immuno-oncology therapies. Immuno-oncology therapies which harness the body’ s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. ... In this video Director Sue Marett discusses the opportunities

  • Video: Immuno-oncology therapies

    Video: Immuno-oncology therapies. Immuno-oncology therapies which harness the body’ s own defences to fight off tumours are widely acknowledged as the new frontier in cancer treatment. ... In this video Director Sue Marett discusses the opportunities

More from PMHub
Approximately 20 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics